3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Prostatic Neoplasms
3
Urinary Bladder Neoplasms
2
Breast Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Hodgkin Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
Doxorubicin
33
Ifosfamide
23
Gemcitabine
19
pazopanib
18
Cyclophosphamide
16
Radiotherapy
15
pembrolizumab
13
Filgrastim
12
Docetaxel
12
Bevacizumab
10
Vincristine
9
Sirolimus
9
Irinotecan
9
Etoposide
9
olaratumab
7
eribulin
7
Sorafenib
7
Radiation
7
temsirolimus
6
Temozolomide
6
Mesna
6
Magnetic Resonance Spectroscopy
6
Cisplatin
6
tazemetostat
5
cixutumumab
5
Trabectedin
5
Radiosurgery
5
Nivolumab
5
Ipilimumab
5
Granulocyte Colony-Stimulating Factor
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Sarcoma
×
Genistein
×
Clear all
NCT02624388
2024-05-06
UVA-Gen001
University of Virginia
Phase 2
Terminated
4 enrolled
16 charts